PLOD1 and polycystic ovary syndrome: Moreover, in a recent study comparing healthy women in the follicular phase with polycystic ovarian syndrome and HA women, subcutaneous administration of MVT‐602 (doses 0.01 and 0.03 nmol/kg) resulted in similar LH increases in the PCOS and healthy groups.89